Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rang in Aktien #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Aktienkurs
$0.07600875
Zuletzt synchronisiert: 2024-11-20
Marktkapitalisierung
$2.06M
Veränderung (1 Tag)
-0.51%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Quantum Genomics S.A. (ALQGC)

Kategorie

Healthcare
P/S-Verhältnis für Quantum Genomics S.A. (ALQGC)
P/S-Verhältnis zum August 2026 TTM: 499.95K
Laut den neuesten Finanzberichten und dem Aktienkurs von Quantum Genomics S.A. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 499.95K. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 186.65.
P/S-Verlauf für Quantum Genomics S.A. von 2009 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 499.95K -0.53%
2024 502.59K 269,175.26%
2023 186.65 11,422.08%
2022 1.62 -95.60%
2021 36.83 -32.65%
2020 54.68 39.21%
2019 39.28 -99.83%
2018 22.77K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 406.74 397.85%
2014 81.70 -94.18%
2013 1.40K 15.20%
2012 1.22K 290.81%
2011 311.74 0.00%
2010 311.74 -14.29%
2009 363.69 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -100.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -100.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -100.00%
BE